President and CEO Jim Davis said he believes PAMA reform will pass this year but said another temporary delay will likely be needed to postpone cuts slated for February 1.

The physical and digital biobank supports the integration of artificial intelligence in acute care diagnostics development.

Last week, readers were most interested in a story about concerns about BillionToOne's Unity NIPT due to false negative results.

The tests run on the company's TruVerus benchtop instrument, which provides results from a blood sample in minutes.

For full-year 2025, MDxHealth's preliminary revenues are $109 million, up 21 percent from 90.0 million in 2024. It billed 49,180 tissue-based units, up from 18 percent year over year, and 71,920 ...

The company said its preliminary revenues for the fourth quarter were at least $21 million, and its full-year 2025 revenues are expected to grow to $77 million.

The company said that the sale of its medical device testing business would allow it to focus on core areas of preclinical drug development and chemical testing.

The bill was one of several discussed during a Thursday hearing by the Health Subcommittee of the House of Representatives' ...

Coupling biomarker-guided screening with a targeted treatment bundle reduced newborn mortality, hospital stays, and other complications over standard care, according to a recent study.

The companies aim to advance the development of next-generation epigenetic sequencing and liquid biopsy tools for colorectal cancer detection.

The next phase of funding will allow the team to launch a clinical trial to test a novel way of making early gastric tumors easier to identify during endoscopy procedures.

The STELLAR-316 trial will use Natera's Signatera assay to identify MRD-positive patients for trial enrollment and to monitor therapy response.